Join the Oncology Voice Network. Join for Free
How and Why Medical Affairs Can Support Diversity in Clinical Trials
diversity in clinical trials role of MSLs FDA guidance on diversity patient-centric approaches cultural awareness and allyship

How and Why Medical Affairs Can Support Diversity in Clinical Trials


Share This Article


Summary

In this episode, Tom Caravela is joined by Brad Atkinson, Brian Wilson, and Christina Wright to explore the critical role of diversity in clinical trials and the MSL’s part in fostering inclusivity. The discussion covers FDA guidance on diversity, challenges in therapeutic areas, and the importance of patient-centric approaches. The speakers delve into the strategic roles of MSLs in education and the historical context of diversity in clinical trials. They provide actionable strategies for field medical teams to enhance trial diversity and emphasize the significance of cultural awareness and allyship. The episode concludes with reflections and a call to action for promoting diversity in medical settings.

Christina Wright, Brad Atkinson and Brian Wilson discuss the important role Medical Affairs/MSLs can play in supporting diversity in clinical trials

The group discusses…

👉 Why does medical affairs need to be involved in diversity clinical trial initiatives?

👉 How can field medical get comfortable with the D and I conversation?

👉 What resources can be helpful

👉 3 Pillars of “Allyship”

👉 Why insights are currency

Click for Source
diversity in clinical trials, role of MSLs, FDA guidance on diversity, patient-centric approaches, cultural awareness and allyship

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to create HIGH performing MSLs, teams and MSL leaders
Partner Avatar MSL Talk: Tom Caravela, Mike Penkethman

How to create HIGH performing MSLs, teams and MSL leaders

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Explore OVN